Mucosal (e.g., Nasal, Etc.) Patents (Class 424/434)
  • Patent number: 11369576
    Abstract: A method for creating a consolidated compound for delivering an immunomodulatory and imiquimod to a patient, comprising diluting immunomodulator extract to a desired dilution by transferring a desired quantity of the concentrated immunomodulator to an associated sterile container, the associated sterile container having a defined volume of diluted immunomodulator after dilution thereof, providing a viscous encapsulation material, selecting a prescribed amount of concentrated immunomodulator, the prescribed amount defined as that amount of the diluted immunomodulator extract required to provide a number of doses equal to the number of dispensable increments from the container containing the viscous encapsulation material, introducing the selected amount of each of the diluted immunomodulator extract into the viscous encapsulation material, introducing an amount of imiquimod into the viscous encapsulation material, and mixing the introduced amount of each of the diluted immunomodulator extracts and the introduc
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: June 28, 2022
    Assignee: AVRIO GENETICS LLC
    Inventors: James Strader, Jovan Hutton Pulitzer
  • Patent number: 11291626
    Abstract: A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder, to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.
    Type: Grant
    Filed: September 14, 2011
    Date of Patent: April 5, 2022
    Assignee: OptiNose AS
    Inventor: Per Gisle Djupesland
  • Patent number: 11273163
    Abstract: A method of treating a subject in need of anti-Coronavirus treatment comprising prophylactic or therapeutic treatment, with an antiviral effective amount of an Azelastine compound, wherein the antiviral effective amount is 0.1-500 ?g per dose; use of an Azelastine compound as an antiviral substance in a medicinal product for treating a biological surface to prevent from Coronavirus infection and/or Coronavirus spread, and use of an Azelastine compound as viral disinfectant.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: March 15, 2022
    Assignee: CEBINA GMBH
    Inventors: Eszter Nagy, Gabor Nagy, Valeria Szijarto, Robert Konrat
  • Patent number: 11246875
    Abstract: Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: February 15, 2022
    Assignee: TherapeuticsMD, Inc.
    Inventors: Brian A. Bernick, Julia M. Amadio, Sebastian Mirkin
  • Patent number: 11173114
    Abstract: An oral soluble film contains at least one active agent. Alternatively, a multi-layered film includes a plurality of layers, at least one at least one of the plurality of layers being an oral soluble film layer containing at least one active agent. The oral soluble film may be made, e.g., by a method comprising providing a well of a predetermined size; depositing a film forming composition in the well; metering a predetermined amount of an active agent composition in the well separately from the film forming composition, the active agent composition being different than the film forming composition, the film forming composition and the active agent composition forming a single layer in the well; and drying the single layer in the well to form the oral soluble film containing the at least one active agent.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: November 16, 2021
    Assignee: NOVA Thin Film Pharmaceuticals LLC
    Inventors: Richard C. Fuisz, Joseph M. Fuisz, Madhu Hariharan
  • Patent number: 11129792
    Abstract: Use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: September 28, 2021
    Assignee: Modoral Brands Inc.
    Inventors: Anders Axelsson, Arne Kristensen, Henri Hansson
  • Patent number: 11129612
    Abstract: Tissue adhesions using surgical adjuncts and medicants are provided. In general, an implantable adjunct can have one or more medicants releasably retained therein that are configured to induce tissue adhesions. The adjunct can be configured to be applied to lung tissue in conjunction with surgical staples using a surgical stapler. Pleurodesis can be encouraged through delivery of the adjunct to the lung tissue.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: September 28, 2021
    Assignee: Cilag GmbH International
    Inventors: Frederick E. Shelton, IV, Jason L. Harris, Michael J. Vendely, Charles J. Scheib
  • Patent number: 11090290
    Abstract: The present invention pertains to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and Clonidine and/or Clonidine derivatives as a sole active ingredient for use in the prevention of skin injury resulting from radiotherapy by transmucocal administration.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: August 17, 2021
    Assignee: MONOPAR THERAPEUTICS, INC.
    Inventors: Bérangère Vasseur-Demarcy, Pierre Attali
  • Patent number: 11077119
    Abstract: A method of treating a subject for a brain disease associated with cognitive impairment, including administering to a subject a chemical substance according to GLN-1062 or salt thereof: wherein the treatment includes transmucosal administration of a therapeutically effective amount of GLN 1062 or salt thereof in the oral cavity of the subject.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: August 3, 2021
    Assignee: Neurodyn Life Sciences Inc.
    Inventor: Alfred Maelicke
  • Patent number: 11045181
    Abstract: Catheter system, devices and methods for diagnosing and treating lateral stenosis causing back pain and or leg pain. The devices comprise a tubular part for insertion into a working cannula to self-position itself safely within the foramen, and minimize the risk of displacement medially or laterally, to prevent nerve or dura injury. An expandable membrane is configured to maintain the catheter device within the foramen. Expansion of this membrane would decompress the nerve within the foramen by opening the foraminal canal as the membrane expands.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: June 29, 2021
    Inventors: Fred F. Naraghi, Brandon Naraghi
  • Patent number: 11033594
    Abstract: Disclosed herein are orally acceptable topical analgesic gels comprising a mixture of analgesic oils comprising (a) clove oil and/or eugenol, (b) a cooling agent, and (c) camphor, in an orally acceptable gel base, the gel base comprising an anionic polymer and a basic amino acid, and the analgesic gel providing controlled release of the mixture of analgesic oils following application to a tooth together with a methods of making and using the same.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: June 15, 2021
    Assignee: Colgate-Palmolive Company
    Inventors: Shashank Potnis, Ravi Subramanyam, Rajitha Nair
  • Patent number: 11000484
    Abstract: Various methods for diagnosing and treating heart conditions are disclosed herein. According to one method, nitric oxide is delivered to a patient's lungs when the patient has one or more symptoms of a heart condition. The patient is diagnosed as suffering from a heart condition when a symptom of a heart condition subsides after nitric oxide delivery.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: May 11, 2021
    Assignee: Vero Biotech LLC
    Inventor: David H. Fine
  • Patent number: 10960075
    Abstract: A composition includes an oral thin film pharmaceutical dosage form configured to disintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva. The dosage can completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: March 30, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Patent number: 10959450
    Abstract: Disclosed is a food composition relieving the symptoms of various kinds of viral diseases or diseases suspected to be viral diseases. The food composition according to the present invention contains coix, xylitol, vitamin C, manuka honey, frankincense, myrrh and propolis in the form of powders, liquid or extract.
    Type: Grant
    Filed: April 22, 2018
    Date of Patent: March 30, 2021
    Inventor: Heong Jun Yu
  • Patent number: 10874650
    Abstract: Compositions for treatment or prevention of viral infections, such as influenza A and B, coronaviruses, including but not limited to COVID-19, and rhinoviruses, along with related treatment methods. Certain compositions according to preferred embodiments of the invention may comprise chlorpheniramine, xylitol, and other inactive ingredients, such as aloe vera and/or grapefruit seed extract.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: December 29, 2020
    Inventor: Gustavo Ferrer
  • Patent number: 10874658
    Abstract: Sublingual formulations containing an opioid, preferably, fentanyl or a pharmaceutically acceptable salt or ester thereof, naloxone or a pharmaceutically acceptable salt or ester thereof, and a terpene; as well as methods of treating pain by administering the formulations of the invention to a patient in need thereof.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: December 29, 2020
    Assignee: HIKMA PHARMACEUTICALS USA INC.
    Inventors: Ning Shan, Rajesh R. Wakaskar, Edwin A. Baldwin, Andrew B. Schlinkert, Min Wu, Ningxin Yan
  • Patent number: 10849868
    Abstract: Inventive subject matter disclosed herein includes a method of treating a chronic wound. The method includes mechanically debriding a chronic wound; and applying a formulation to the wound for 5 to 60 seconds, the formulation including: phenolsulfonic acid—37% by weight; guaiacolsulfonic acid—24% by weight; free sulfuric acid—29% by weight; and water—10% by weight.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: December 1, 2020
    Assignee: EPIEN Medical, Inc.
    Inventors: Michael Basara, Matthew J. Watkins, James Bracke
  • Patent number: 10836714
    Abstract: Ketamine derivatives and pharmaceutical compositions thereof are disclosed. When administered orally the ketamine derivatives provide increased bioavailability of ketamine in the systemic circulation. The ketamine derivatives can be used to treat neurological diseases, psychological diseases and pain.
    Type: Grant
    Filed: April 2, 2020
    Date of Patent: November 17, 2020
    Assignee: XW LABORATORIES INC.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Hao-Wei Shih, Wai-Si Eng
  • Patent number: 10736850
    Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.
    Type: Grant
    Filed: August 12, 2008
    Date of Patent: August 11, 2020
    Assignee: OHEMO Life Sciences Inc.
    Inventors: Manish S. Shah, Ray Difalco
  • Patent number: 10722494
    Abstract: The instant invention is generally directed to a patient-friendly drug delivery system for targeted populations, such as pediatric and geriatric patients. Specifically, the present invention relates to a pharmaceutical composition in the form of mini-tablets. Even more specifically, the present invention relates to a pharmaceutical composition comprising a therapeutically-effective amount of melatonin in the form of mini-tablets.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: July 28, 2020
    Assignee: Neurim Pharmaceuticals Ltd.
    Inventors: Moshe Laudon, Nava Zisapel
  • Patent number: 10702509
    Abstract: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: July 7, 2020
    Assignee: NewMarket Pharmaceuticals LLC
    Inventors: David Rock, Mark Ridall
  • Patent number: 10695335
    Abstract: Provided is a patch preparation that has improved adhesion to an adherend so as to enable a drug, especially, a systemically active drug to be stably and continuously administered over an extended period. The patch preparation has a layered structure comprising a patch layer including an adhesive plaster containing a drug and a patch support, and a cover layer in this order from a side attached to a skin. In the patch preparation, a buffer material is disposed between the patch support of the patch layer and the cover layer, the cover layer has a size covering an area beyond peripheral edges of the patch layer, and a shielding film is further disposed between the cover layer and the buffer material.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: June 30, 2020
    Assignee: Teikoku Seiyaku Co., Ltd.
    Inventor: Satoshi Kawakami
  • Patent number: 10688069
    Abstract: A topical composition that includes L-arginine that is used as a sports health composition. The composition can further include forskolin. Disclosed is a method of using the topical composition.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: June 23, 2020
    Assignee: REV Pharmaceuticals LLC
    Inventors: Beth Anne-Szkudlarek Brown, Anthony Lemus, Marnie L. Peterson
  • Patent number: 10624793
    Abstract: An article 1 comprises a hydrophilic foam layer 3; a reservoir cover 5 in contact with a first main surface of the hydrophilic foam layer 3, the reservoir cover 5 enclosing a reservoir cavity 7 together with the first main surface of the hydrophilic foam layer 3, the reservoir cavity 7 being for containing a fluid; and a hydrophobic foam layer 9 formed over the first main surface of the hydrophilic foam layer 3 and the reservoir cover 5. Fluid can be dispensed from the reservoir cavity 7 through a lower surface of the hydrophilic foam layer 3 by pressing on the hydrophobic foam layer 9 so that the reservoir cover 5 is compressed.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: April 21, 2020
    Assignee: DENTMED LIMITED
    Inventor: Ian Malcolm Vickery
  • Patent number: 10625242
    Abstract: A solid substrate for the extraction, stabilization, and storage of proteins is provided. The substrate includes: a polysaccharide, such as melezitose under a substantially dry state. The substrate is configured to extract proteins from a sample and stabilize the extracted proteins in a dry format under ambient conditions for a prolonged period of time. Methods for collecting and recovering the proteins stored in the dry solid substrate are also described.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: April 21, 2020
    Assignee: General Electric Company
    Inventors: Ernest William Kovacs, Frank John Mondello, Erik Leeming Kvam, Bing Li
  • Patent number: 10617143
    Abstract: A smokeless tobacco product is provided that includes a tobacco material in the form of a tobacco extract, a particulate tobacco material, or a combination thereof. In some embodiments, the smokeless tobacco product is substantially translucent. Methods for making and using the smokeless tobacco product are also provided. The smokeless tobacco product can include isomalt, maltitol syrup, particulate tobacco, and a translucent tobacco extract prepared by ultrafiltration.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: April 14, 2020
    Assignee: R.J. Reynolds Tobacco Company
    Inventor: Darrell Eugene Holton, Jr.
  • Patent number: 10596187
    Abstract: Provided herein are compositions, for example: oral rehydration compositions, beverages, food items, methods and uses, which utilise resistant starch to prevent or treat dehydration, including dehydration which is caused by diarrhoea. Beverages, food items and oral rehydration solutions including a resistant starch, which are suitable for aiding in the maintenance and restoration of hydration levels in individuals undertaking physical activities, including sports, are also disclosed.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 24, 2020
    Assignees: Yale University, Flinders University of South Australia, Balakrishnan Siddartha Ramakrishna
    Inventors: Balakrishnan Siddartha Ramakrishna, Graeme Paul Young, Ian Lewis Brown, Henry Joseph Binder
  • Patent number: 10590403
    Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acinetobacter lysin polypeptides.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: March 17, 2020
    Assignee: The Rockefeller University
    Inventors: Vincent Fischetti, Raymond Schuch, Rolf Lood, Benjamin Winer
  • Patent number: 10583081
    Abstract: A kit that is made of an apparatus comprising a bottle and a nozzle sprayer, and a pharmaceutical formulation comprising dyclonine HCL, triamcinolone, dicyclomine, and dental powder. A method for treating mouth ulcers comprising administering to a patient a formulation comprising dyclonine HCL, triamcinolone, dicyclomine, and dental powder to an affected area.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: March 10, 2020
    Inventor: Richard A. Myers
  • Patent number: 10548819
    Abstract: The invention features a composition which can or is to be used in a dental retraction, the composition comprising liquid a liquid and a layer type 1:1 silicate mineral and a layer type 2:1 silicate mineral in a ratio from about 50/50 to 5/95 wt.-% with respect to each other. The invention also relates to a container containing the dental retraction composition and to a kit comprising parts A and B, wherein part A comprises the dental retraction composition and part B comprises at least one accessory selected from the group of applier, dental impression material, retraction cap(s), a container for storing and dispensing the composition and combinations thereof. The invention further features a process of dispensing a dental retraction composition, the process comprising the steps: providing a dental retraction composition contained in a container, placing the container in an applier, and using the applier for dispensing the dental retraction composition out of the container.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: February 4, 2020
    Assignee: 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: Andreas R. Maurer, Christoph Schulte, Rüdiger Hampe, Johannes M. Leykauff, Helmut Pauser
  • Patent number: 10532033
    Abstract: The invention relates to a transdermal therapeutic system on the basis of polysiloxane which contains microreservoirs filled with an active substance and one ambiphilic solvent.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: January 14, 2020
    Assignee: LTS LOHMANN Therapie-Systeme AG
    Inventor: Walter Müller
  • Patent number: 10507216
    Abstract: A method for olfactory improvement with saccharide. The saccharide is a chitin-based material, proteoglycan, glycosaminoglycan, amino monosaccharide, N-acylated amino monosaccharide or a combination thereof.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: December 17, 2019
    Inventor: Tsung-Wei Huang
  • Patent number: 10493071
    Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: December 3, 2019
    Assignee: HELPERBY THERAPEUTICS LIMITED
    Inventors: Petra Helga Beck, Marc Barry Brown, David Edward Clark, Anthony Coates, Hazel Joan Dyke, Yanmin Hu, Derek John Londesbrough, Keith Mills, Thomas David Pallin, Gary Patrick Reid, Gerlinda Stoddart
  • Patent number: 10485817
    Abstract: The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: November 26, 2019
    Assignee: TX MEDIC AB
    Inventors: Anders Waas, Lars Bruce, Adam Bruce
  • Patent number: 10471021
    Abstract: The invention relates to a transdermal therapeutic system (TTS), which is suited for the administration of a peptide to a patient through skin treated with ablation. The transdermal therapeutic system includes a back layer and an active substance-containing layer that contains at least one peptide and a carrier substance, preferably as a textile web material.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: November 12, 2019
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Michael Horstmann, Gerd Hoffmann, Sandra Wiedersberg
  • Patent number: 10456386
    Abstract: The present disclosure relates to a pharmaceutical composition comprising as active substance betahistine or a pharmaceutically acceptable salt thereof, for use in the treatment of otological or neurological disorders in a human subject by intranasal application.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: October 29, 2019
    Assignee: OTOLANUM AG
    Inventors: Christopher John Wraight, Thomas Meyer
  • Patent number: 10407423
    Abstract: It relates to the compounds of formula (I), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures thereof, wherein A, R1, R2, and R3 are as defined herein, which are inhibitors of one or more DNMTs selected from the group consisting of DNMT1, DNMT3A and DNMT3B. It also relates to pharmaceutical or veterinary compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of cancer, fibrosis and/or immunomodulation.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: September 10, 2019
    Assignee: FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA
    Inventors: Xabier Aguirre Ena, Julen Oyarzabal Santamarina, Felipe Prósper Cardoso, Maria Obdulia Rabal Gracia, Edurne San José Enériz, Juan Antonio Sánchez Arias
  • Patent number: 10391087
    Abstract: The present invention is effective for the treatment and relief of cough produced by posterior nasal secretion, through the use of the combination of Oximetazoline and Ipratropium. The active agents enunciated in the combination of the present invention have been used and marketed separately with different uses to those of the present invention. The oxymetazoline to eliminate nasal secretion and congestion (obstruction), and ipratropium bromide is marketed for the purpose of dilating the bronchial tubes in asthmatic patients with chronic obstructive pulmonary disease, although experimentally it has also been used to decrease nasal secretion. Both active agents, together or separately have not been used so far as antitussives intranasally. The cough produced by the posterior nasal secretion, is the most frequent cause of cough in the human being of any age, the present invention is effective for the treatment and relief of said symptom.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: August 27, 2019
    Inventor: Pablo Cortes Borrego
  • Patent number: 10370402
    Abstract: The invention relates to a novel crystallization process for preparing fluticasone propionate as crystalline form 1 polymorph with controlled particle size and suitable for micronization. Said process comprises the step of dissolving fluticasone propionate in acetone or in a mixture of acetone and water and then adding this solution to water or to a mixture of water 10 and acetone, thereby causing fluticasone propionate to crystallize out of the solution as crystalline form.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: August 6, 2019
    Assignee: Pfizer Limited
    Inventors: Martyn David Ticehurst, Ivan Marziano, Eleftherios Kougoulos
  • Patent number: 10272125
    Abstract: Transdermal delivery devices for the delivery of cannabidiol (CBD) and related moieties are shown and described. In a reservoir-patch design, a microporous, hydrophilic membrane and a backing define a reservoir that houses a mixture of CBD, a polar liquid, and a gelling agent. In a monolithic design, a release liner is coated with a mixture of CBD and a PIB or amine-compatible silicone skin adhesive laminated to the backing material. In using CBD as a pure compound or as one to combine with other moieties, the invention is able to control delivery better than the prior art.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: April 30, 2019
    Assignee: Life Tech Global, LLC
    Inventor: Ludwig Weimann
  • Patent number: 10265309
    Abstract: Sublingual formulations containing an opioid, preferably, fentanyl or a pharmaceutically acceptable salt or ester thereof, naloxone or a pharmaceutically acceptable salt or ester thereof, and a terpene; as well as methods of treating pain by administering the formulations of the invention to a patient in need thereof.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: April 23, 2019
    Assignee: INSYS DEVELOPMENT COMPANY, INC.
    Inventors: Ning Shan, Rajesh R. Wakaskar, Edwin A. Baldwin, Andrew B. Schlinkert, Min Wu, Ningxin Yan
  • Patent number: 10258681
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: April 16, 2019
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Patent number: 10245034
    Abstract: Tissue adhesions using surgical adjuncts and medicants are provided. In general, an implantable adjunct can have one or more medicants releasably retained therein that are configured to induce tissue adhesions. The adjunct can be configured to be applied to lung tissue in conjunction with surgical staples using a surgical stapler. Pleurodesis can be encouraged through delivery of the adjunct to the lung tissue.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: April 2, 2019
    Assignee: Ethicon LLC
    Inventors: Frederick E. Shelton, IV, Jason L. Harris, Michael J. Vendely, Charles J. Scheib
  • Patent number: 10143655
    Abstract: Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: December 4, 2018
    Assignee: MannKind Corporation
    Inventors: Mark Hokenson, Keith A. Oberg
  • Patent number: 10130581
    Abstract: Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: November 20, 2018
    Assignee: MannKind Corporation
    Inventors: Bryan R. Wilson, Marshall Grant
  • Patent number: 10098379
    Abstract: A device for simulating a chemosenzation of smoking includes an outer layer, a porous medium and a chemesthetic agent. The porous medium is disposed within the outer layer. The chemesthetic agent is disposed within the porous medium and activates a TRP channel.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: October 16, 2018
    Assignee: Sentiens, LLC
    Inventors: Reid von Borstel, Dennis Tan, John Siverling, Inna S. Timokhina
  • Patent number: 10045984
    Abstract: The present invention provides a composition comprising zinc and trimethoprim, particularly in a weight ration of about 1:3 to about 1:7, as well as a sustained- or prolonged-release preparation which comprises trimethoprim and zinc and a biodegradable polymer providing a clinically useful composition which has prolonged release over a long period of time.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: August 14, 2018
    Inventor: Magdi El-Habbal
  • Patent number: 10016534
    Abstract: The present invention relates to protein biocoacervates and biomaterials vessel graft systems used in cardiovascular applications and other medical applications, the components utilized in the vessel graft systems and the methods of making and using such systems. More specifically the present invention relates to protein biocoacervates and biomaterials vessel graft systems used in various medical applications and/or the devices used in such vessel graft systems including, but not limited to, vessel grafts as drug delivery devices for the controlled release of pharmacologically active agents, tubular grafts, vascular grafts, protein biomaterial sutures and biomeshes, protein biomaterial adhesives and glues, and other biocompatible biocoacervate or biomaterial devices used in the vessel graft systems of the present invention.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: July 10, 2018
    Assignee: Gel-Del Technologies, Inc.
    Inventor: David B. Masters
  • Patent number: 9999243
    Abstract: An exhausted-tobacco lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix, exhausted-tobacco fiber, and one or more additives (e.g. nicotine or a derivative thereof) dispersed in the soluble-fiber matrix. In some cases, an exhausted-tobacco lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in exhausted-tobacco lozenge provided herein can include maltodextrin. The exhausted-tobacco lozenge is adapted to release the nicotine or a derivative thereof from the body when the body is received within the oral cavity of an adult tobacco consumer and exposed to saliva. A method of making exhausted-tobacco lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, exhausted-tobacco fiber, one or more additives (e.g., nicotine), and less than 15 weight percent water while maintaining a mixture temperature of less than 150° C.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: June 19, 2018
    Assignee: ALTRIA CLIENT SERVICES LLC
    Inventors: Feng Gao, Diane L. Gee, Phillip M. Hulan, Shuzhong Zhuang, William J. Burke
  • Patent number: 9993444
    Abstract: The chronic use of p-adrenergic inverse agonists such as nadolol, carvedilol, and ICI-118,551 provides an improved method for the treatment of mucus hypersecretion in subjects with such mucus hypersecretion. One aspect of a method according to the present invention is a method of preventing or controlling mucus hypersecretion in the respiratory tract comprising administering a therapeutically effective quantity of a p-adrenergic inverse agonist to a subject with mucus hypersecretion or at risk of mucus hypersecretion. The invention further encompasses pharmaceutical compositions comprising the p-adrenergic inverse agonist and the additional compound.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: June 12, 2018
    Assignee: INVION, INC.
    Inventors: Richard A. Bond, Mitchell Glass